The adverse effects of calcium channel blockers (CCBs) vary significantly between the two major classes—dihydropyridines and non-dihydropyridines—due to their differing mechanisms of action. Dihydropyridines, such as amlodipine, nifedipine, and felodipine, primarily act on vascular smooth muscle, leading to common side effects like lightheadedness, flushing, headaches, and peripheral edema. Peripheral edema, in particular, results from fluid redistribution from the intravascular space to the interstitial tissues. Although this class is mainly associated with vasodilation, more severe complications such as acute myocardial infarction (AMI), exacerbated angina, acute hypotension, syncope, erythema multiforme, and hepatitis may also occur. These severe adverse reactions are less common but may vary depending on the specific dihydropyridine agent used.
Non-dihydropyridines, such as verapamil and diltiazem, act more directly on the heart, resulting in side effects like constipation, orthostatic hypotension, elevated liver enzymes, dizziness, and fatigue. More serious adverse reactions include bradycardia, reflex tachycardia, atrioventricular (AV) block, arrhythmias, severe hypotension, and heart failure exacerbation. These agents can also cause Stevens-Johnson syndrome, paralytic ileus, peripheral edema, hepatotoxicity, and congestive heart failure in some cases. As with dihydropyridines, the incidence and severity of these adverse effects can vary based on the specific drug and dosage.
